Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-786 in Intermittent Explosive Disorder
NCT03420222Phase 2Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deudextromethorphan in intermittent explosive disorder (IED), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jan 2018; status: terminated.
02
Drugs
deudextromethorphan
03
Conditions
intermittent explosive disorder (IED)
Beyond the preview
Go deeper on NCT03420222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03420222.